Literature DB >> 17036562

Psychiatric adverse effects of corticosteroids.

Thomas P Warrington1, J Michael Bostwick.   

Abstract

Psychiatric adverse effects during systemic corticosteroid therapy are common. Two large meta-analyses found that severe reactions occurred in nearly 6% of patients, and mild to moderate reactions occurred in about 28%. Although disturbances of mood, cognition, sleep, and behavior as well as frank delirium or even psychosis are possible, the most common adverse effects of short-term corticosteroid therapy are euphoria and hypomania. Conversely, long-term therapy tends to induce depressive symptoms. Dosage is directly related to the incidence of adverse effects but is not related to the timing, severity, or duration of these effects. Neither the presence nor the absence of previous reactions predicts adverse responses to subsequent courses of corticosteroids. Corticosteroid-induced symptoms frequently present early in a treatment cycle and typically resolve with dosage reduction or discontinuation of corticosterolds. In severe cases or situations in which the dose cannot be reduced, antipsychotics or mood stabilizers may be required. This review offers an approach to identifying and managing corticosteroid-induced psychiatric syndromes based on the type of symptoms and anticipated duration of corticosteroid treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17036562     DOI: 10.4065/81.10.1361

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  86 in total

1.  Inhaled steroid-induced mania in an adolescent girl: a case report.

Authors:  Saira Khan; Jabeen Hayat; Shakeel Raza
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus.

Authors:  April Jorge; Apinya Lertratanakul; Jungwha Lee; William Pearce; David McPherson; Trina Thompson; Emma Barinas-Mitchell; Rosalind Ramsey-Goldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-11-21       Impact factor: 4.794

3.  Psychiatric adverse drug reactions to glucocorticoids in children and adolescents: a much higher risk with elevated doses.

Authors:  Neda Tavassoli; Julie Montastruc-Fournier; Jean Louis Montastruc
Journal:  Br J Clin Pharmacol       Date:  2008-05-15       Impact factor: 4.335

4.  Improvement of neuropsychiatric symptoms in multiple sclerosis subsequent to high-dose corticosteroid treatment.

Authors:  Jan Thöne; Elke Kessler
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

5.  Systemic corticosteroid monotherapy for clinically diagnosed acute rhinosinusitis: a randomized controlled trial.

Authors:  Roderick P Venekamp; Marc J M Bonten; Maroeska M Rovers; Theo J M Verheij; Alfred P E Sachs
Journal:  CMAJ       Date:  2012-08-07       Impact factor: 8.262

Review 6.  The neurology of solid organ transplantation.

Authors:  J David Avila; Saša Živković
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 7.  Corticosteroids and Cognition: A Meta-Analysis.

Authors:  Catherine E Prado; Simon F Crowe
Journal:  Neuropsychol Rev       Date:  2019-05-26       Impact factor: 7.444

Review 8.  Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus.

Authors:  Samir D Bhangle; Neil Kramer; Elliot D Rosenstein
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

9.  Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa.

Authors:  Elizabeth A Lawson; Daniel Donoho; Karen K Miller; Madhusmita Misra; Erinne Meenaghan; Janet Lydecker; Tamara Wexler; David B Herzog; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

10.  Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors.

Authors:  Monica Smith; Lisa Bero; Lynne Carber
Journal:  Chiropr Osteopat       Date:  2010-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.